Peijia Medical reports 16-19% revenue growth in H1

Peijia Medical Limited reported preliminary revenue of RMB350-360 million for the six months to June 30, up 16.2-19.5% from RMB301.2 million in the same period last year.

Growth was driven by increased market share in China's transcatheter aortic valve replacement market and a shift to premium products. The company's valve replacement portfolio expanded to over 720 hospitals, with implantations exceeding 2,050 units, up 18.8%.

Final results are expected in August.